Literature DB >> 19004416

Gamma hydroxybutyrate: an ethnographic study of recreational use and abuse.

Steven J Lee1, Petros Levounis.   

Abstract

Gamma hydroxybutyrate (GHB) is a psychoactive substance with complex neurophysiological activity and significant potential for abuse, addiction, and dangerous toxicity. In this study, a semistructured interview was administered to 17 subjects to investigate GHB use, including: manner of use; setting; positive and negative consequences; other drug history; and sexual practices. Respondents were overwhelmingly male, but otherwise had a broad demographic background. Settings varied from nightclubs to private use at home. There was significant variability in the drug obtained, which subjects found problematic because of the narrow therapeutic window and ease of accidental overdose. Common positive experiences included increased sexual desire, decreased sexual inhibitions, and decreased anxiety. Common negative consequences included oversedation, loss of consciousness, motor incoordination, and mental confusion. Nine subjects reported that they would use GHB again, some despite severe negative consequences. Although most subjects reported negative experiences, only three felt their use was problematic, and none sought treatment for GHB abuse or addiction. Subjects were highly drug-experienced, most commonly using MDMA, ketamine, cocaine, alcohol, and methamphetamine. Some reported that GHB could cause poor decision making in sexual situations. This effect has significant ramifications for issues such as date rape and control of sexually transmitted diseases, such as HIV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004416     DOI: 10.1080/02791072.2008.10400639

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  9 in total

1.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

Review 2.  Illicit substance use in pregnancy - a review.

Authors:  Katherine Scott; Karin Lust
Journal:  Obstet Med       Date:  2010-09-17

3.  Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.

Authors:  Petra S van Nieuwenhuijzen; Leonora E Long; Glenn E Hunt; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2010-08-21       Impact factor: 4.530

4.  A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use.

Authors:  L A R Stein; Rebecca Lebeau; Mary Clair; Rosemarie Martin; Monte Bryant; Susan Storti; Peter Monti
Journal:  Am J Addict       Date:  2010-11-12

5.  Psychosis in the context of sodium oxybate therapy.

Authors:  Jody Langford; William L Gross
Journal:  J Clin Sleep Med       Date:  2011-12-15       Impact factor: 4.062

6.  Preliminary web-based measures development for GHB: expectancies, functions, and withdrawal.

Authors:  L A R Stein; Rebecca Lebeau; Mary Clair; Rosemarie Martin; Monte Bryant; Susan Storti
Journal:  Am J Drug Alcohol Abuse       Date:  2011-12-19       Impact factor: 3.829

7.  Gamma-Hydroxybutyrate Increases Resting-State Limbic Perfusion and Body and Emotion Awareness in Humans.

Authors:  Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz
Journal:  Neuropsychopharmacology       Date:  2017-05-31       Impact factor: 7.853

Review 8.  Toxicological Characterization of GHB as a Performance-Enhancing Drug.

Authors:  Arianna Giorgetti; Francesco Paolo Busardò; Raffaele Giorgetti
Journal:  Front Psychiatry       Date:  2022-04-18       Impact factor: 5.435

9.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.